

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-6 (canceled)

Claim 7 (currently amended): A method for inhibiting blood coagulation comprising administering a therapeutically effective amount of a composition including a bromelain protease to a subject in need thereof wherein the bromelain protease includes a basic bromelain protease from *Ananas comosus* that has a molecular weight of about 24.4 KDa, an optimal activity at a pH ranging from about 4 to about 5.5 and ~~a~~comprises SEQ ID NO: 1~~7~~, and wherein the bromelain protease stimulates plasmin production, inhibits fibrin production, and inhibits adhesion of thrombocytes on endothelium cells.

Claims 8-10 (canceled)

Claim 11 (currently amended): A medicament comprising a composition including a bromelain protease wherein the bromelain protease includes a basic bromelain protease from *Ananas comosus* that has a molecular weight of about 24.4 KDa, an optimal activity at a pH ranging from about 4 to about 5.5 and ~~a~~comprises SEQ ID NO: 1~~7~~, and wherein the bromelain protease stimulates plasmin production, inhibits fibrin production, and inhibits adhesion of thrombocytes on endothelium cells.

Claim 12 (previously presented): The medicament of claim 11 wherein the bromelain protease is a recombinant bromelain protease.